CoChat
Sign Up
Cited by 34Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysProtein Tyrosine Phosphatases

524P A Phase I, Open-Label, Dose-Escalation Trial of BI 1701963 in Patients (Pts) with KRAS Mutated Solid Tumours: A Snapshot Analysis

Open access
Johnson, M.L., Gort, E., Pant, S., Lolkema, M.P., Sebastian, M., Scheffler, M., Hwang, J., Dünzinger, U. +3 more·2021·Annals of Oncology
DOI 10.1016/j.annonc.2021.08.1046
Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2021.08.1046

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • BI-1701963 has been generally well tolerated, with a maximum tolerated dose reached at 800 mg, and stable disease for up to 18 weeks demonstrated in 7 out of 31 patients with solid tumors harboring KRAS mutations.

    “BI-1701963 has been generally well tolerated, with a maximum tolerated dose reached at 800 mg, and stable disease for up to 18 weeks demonstrated in 7 out of 31 patients with solid tumors harboring KRAS mutations [63].”

    From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [63]

Cited by

Sorted by citations

Related

Authors
Johnson, M. L., Gort, E., Pant, S., Lolkema, M. P., Sebastian, M., Scheffler, M., Hwang, J., Dünzinger, U., Riemann, K., Kitzing, T., & Jänne, P. A.
Affiliations
  • Sarah Cannon (US)
  • University Medical Center Utrecht (NL)
  • The University of Texas MD Anderson Cancer Center (US)
  • Erasmus MC Cancer Institute (NL)
  • University Hospital Frankfurt (DE)
  • University Hospital Cologne (DE)
  • Levine Cancer Institute (US)
  • Boehringer Ingelheim (Germany) (DE)
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2021-09
Volume
32
Pages
S591-S592
ISSN
0923-7534 (ISSN-L)
DOI
10.1016/j.annonc.2021.08.1046
OpenAlex
W3204964496
Cited by
34
References
0
Citations by year
2026: 6 · 2025: 6 · 2024: 13 · 2023: 5 · 2022: 4
FWCI
1.73
Type
journal article
Language
en
Open access
Licence
Locations
Annals of Oncology (publishedVersion)
Funders
Boehringer Ingelheim
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS mutation, solid tumors, SOS1, protein-protein interaction inhibitors, trametinib, maximum tolerated dose, dose-limiting toxicity, monotherapy, small molecule inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review